Stehr, Jan Eric
Lundström, Ingemar
Karlsson, Jan Olof G.
Funding for this research was provided by:
Karlsson-Tunér Invest AS, Norway
Forskningsrådet i Sydöstra Sverige (FORSS-85191)
Article History
Received: 15 July 2019
Accepted: 1 October 2019
First Online: 1 November 2019
Competing interests
: I.L. and J.O.G. are two of the founders of PledPharma AB and own shares in that company. J.O.G.K. is the main owner of the sponsor Karlsson-Tunér Invest AS. J.O.G.K. is inventor on two granted patent families (e.g., US8377969, US8633174, and US9187509; own by PledPharma AB) and a PCT application (WO 2018/087347 A1; own by Karlsson-Tuner Invest AS), covering the therapeutic use of calmangafodipir and fodipir. J.E.S. has no competing interest.